Immutep wins US patent for efti combination therapies
IMMP•Immutep received a US patent covering combinations of eftilagimod alfa with PD-1 pathway inhibitors, bringing its patent portfolio in this family to five. Protection expires March 23, 2038, including an 806-day patent term adjustment.
1. Patent protection extended
The patent covers preparations combining eftilagimod alfa with PD-1 pathway inhibitors. It brings Immutep’s US patent portfolio in this family to five, with protection expiring March 23, 2038, including an 806-day patent term adjustment.
